EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 11
Issue: 6
238-245
Year: 2024

GASTRIC FLOATING DRUG DELIVERY SYSTEMS MATRIX SUSTAINED RELEASE TABLET

Ombabu Goswami[1]*, Dr. Brajesh Kumar Arjariya[2] and Praveen Bhawsar[3]

[1]Research Scholar, [2]Associate Professor, [3]Associate Professor

***Corresponding Author: Ombabu Goswami**
Research Scholar.

Article Received on 23/04/2024 **Article Revised on 13/05/2024** **Article Accepted on 02/06/2024**

ABSTRACT
The integration of gastric floating drug delivery systems (GFDDS) with matrix sustained release tablets represents a promising approach to controlled drug delivery, offering extended gastric retention and sustained release kinetics. This study explores the applications, innovations, regulatory considerations, and commercial viability of GFDDS-matrix tablet integration across various therapeutic areas. Key findings highlight the potential benefits in gastrointestinal disorders, chronic diseases, infectious diseases, and neurological disorders. Innovations such as targeted drug delivery, combination therapy, smart drug delivery systems, and nanotechnology hold promise for enhancing therapeutic outcomes. Regulatory considerations, including compliance with pharmacopeial standards, bioequivalence studies, and stability assessments, are crucial for successful commercialization. Implications for the pharmaceutical industry include opportunities for innovation, market expansion, and improved patient care. Future research directions focus on personalized medicine, precision drug delivery, and collaboration between academia, industry, and regulatory agencies. Overall, integrated GFDDS-matrix tablet formulations offer significant potential for advancing drug delivery technologies and improving global health outcomes.

KEYWORDS: Gastric floating drug delivery systems, matrix sustained release tablets, controlled drug delivery, targeted drug delivery, smart drug delivery systems.

Gastric Floating Drug Delivery Systems (GFDDS)
Gastric Floating Drug Delivery Systems (GFDDS) are a type of drug delivery system designed to prolong the gastric residence time of drugs in the stomach. These systems are particularly useful for drugs that exhibit low solubility or stability in the gastric environment, or those that require localized action in the stomach.[1]

The concept behind GFDDS is to formulate dosage forms that are buoyant in gastric fluids, allowing them to float on the stomach's surface for an extended period. This buoyancy is typically achieved by incorporating gas-generating agents or using low-density materials in the formulation. Once the dosage form floats on the gastric contents, it remains in the stomach, gradually releasing the drug payload over an extended period.[2]

Mechanisms of Floating Drug Delivery
Buoyancy-based Systems
Buoyancy-based systems utilize the principle of buoyancy to keep the dosage form afloat in the gastric fluid. These systems typically incorporate low-density materials or gas-generating agents to achieve buoyancy. The dosage form is formulated with materials that are less dense than gastric fluids, allowing them to float on the surface of the stomach contents. Gas-generating agents, such as sodium bicarbonate, react with gastric acid to produce carbon dioxide bubbles, which get entrapped within the dosage form, creating a buoyant force. Examples of buoyancy-based systems include floating tablets, capsules, and multiparticulate systems.[3-4]

Effervescent Systems
Effervescent systems utilize the generation of gas bubbles to achieve gastric retention. These systems contain effervescent agents, such as citric acid and sodium bicarbonate, which react with gastric fluid to release carbon dioxide gas. The gas bubbles produced within the dosage form increase its volume and decrease its density, causing it to float on the gastric fluid. Effervescent systems are particularly effective for drugs that require rapid onset of action or drugs that are less stable in the gastric environment. Upon administration, the effervescent reaction occurs, leading to the formation of a foam or gas-filled voids within the dosage form, which facilitates gastric retention.[5-6]

Gel Barrier Systems

Gel barrier systems employ the use of hydrophilic polymers that swell upon contact with gastric fluid to form a gel layer around the dosage form. This gel layer acts as a barrier, preventing the dosage form from being emptied from the stomach and prolonging its residence time. The swollen gel layer also provides buoyancy to the dosage form, contributing to its floating behavior. The gel barrier systems are particularly suitable for drugs that require sustained release or localized action in the stomach. Examples of hydrophilic polymers used in gel barrier systems include hydroxypropyl methylcellulose (HPMC), sodium alginate, and polyethylene oxide (PEO).[7-8]

Advantages of GFDDS

1. **Prolonged Gastric Residence Time**: GFDDS are designed to float on the surface of gastric fluids, thereby prolonging their residence time in the stomach. This prolonged gastric retention enhances drug absorption and bioavailability, especially for drugs that are absorbed primarily in the stomach or those that exhibit low solubility.[9-10]
2. **Improved Drug Stability**: Drugs that are sensitive to the acidic environment of the stomach or undergo degradation in the intestinal tract can benefit from GFDDS. By remaining in the stomach for an extended period, these systems protect the drug from degradation, leading to improved stability and efficacy.[11-12]
3. **Controlled Release**: GFDDS can be formulated to provide controlled release of drugs over an extended period. This controlled release profile leads to a more sustained therapeutic effect and allows for less frequent dosing, improving patient compliance and convenience.[13-14]
4. **Reduced Variability in Drug Absorption**: By minimizing the transit of drugs through the gastrointestinal tract, GFDDS can reduce variability in drug absorption. This results in more predictable pharmacokinetics and improved therapeutic outcomes.[15-16]
5. **Localized Action**: Some drugs require localized action in the stomach for the treatment of conditions such as gastric ulcers or gastroesophageal reflux disease (GERD). GFDDS enable targeted delivery of drugs to the stomach, ensuring maximum efficacy at the site of action while minimizing systemic side effects.[17-18]

Matrix Sustained Release Tablet

Matrix sustained release tablets are a formulation approach used in oral drug delivery to achieve controlled and prolonged release of active pharmaceutical ingredients (APIs) over an extended period. These tablets are designed to release the drug in a sustained manner, maintaining therapeutic drug levels in the body for a longer duration, thus reducing the frequency of dosing and improving patient compliance.

Homogeneous Matrix: Matrix tablets are composed of a homogenous mixture of the API and various excipients, which are compressed into a solid tablet form. The uniform distribution of the drug within the matrix ensures consistent drug release characteristics throughout the dosage form.[19-20]

Controlled Release Mechanism: The controlled release of the drug from matrix tablets is achieved through diffusion, erosion, or a combination of both mechanisms.

- **Diffusion-controlled release:** The drug diffuses through the matrix material, which may be hydrophilic polymers, such as hydroxypropyl methylcellulose (HPMC), methylcellulose, or ethylcellulose. The rate of diffusion is determined by factors such as the drug's solubility, molecular weight, and the properties of the matrix material.[21]
- **Erosion-controlled release:** The matrix material gradually erodes over time, releasing the drug as the tablet disintegrates or dissolves in the gastrointestinal tract. Erosion can be controlled by selecting appropriate matrix excipients with specific erosion rates.[22]

Extended Drug Release: Matrix sustained release tablets are designed to provide prolonged drug release profiles, typically ranging from several hours to days, depending on the formulation and drug properties. This extended release profile allows for a steady and sustained therapeutic effect, minimizing fluctuations in drug plasma levels.[23-24]

Dose Proportionality: Matrix tablets can be formulated to achieve dose proportionality, ensuring that the rate and extent of drug release are directly proportional to the dosage strength. This allows for consistent drug delivery and predictable pharmacokinetics across different dosage strengths.[25-26]

Reduced Dosage Frequency: By providing sustained release of the API, matrix tablets reduce the dosing frequency compared to immediate-release formulations. This improvement in dosing regimen enhances patient compliance and convenience, leading to better treatment outcomes.[27-28]

Minimized Peak-to-Trough Fluctuations: The sustained release profile of matrix tablets helps minimize fluctuations in plasma drug concentration, leading to smoother pharmacokinetic profiles. This can reduce the risk of side effects associated with peak drug levels and improve therapeutic efficacy.[29-30]

Formulation Considerations

Matrix Formers

Matrix formers are the key components of sustained release tablets that provide the structure and control the release of the active pharmaceutical ingredient (API) from the tablet matrix. These polymers are selected

based on their ability to form a uniform and stable matrix, as well as their release-controlling properties.[31-32]

Release Modifiers: Release modifiers are excipients added to the formulation to modulate the drug release kinetics from the matrix. These modifiers can include hydrophilic or hydrophobic agents, plasticizers, or pore-forming agents, which alter the diffusion or erosion characteristics of the matrix and influence the release rate of the drug.[33-34]

Excipients: Excipients play a crucial role in the formulation of sustained release tablets by providing various functionalities such as binding, disintegration, lubrication, and stability. Common excipients used in matrix sustained release tablets include fillers, binders, disintegrants, lubricants, and glidants, which contribute to the overall performance and manufacturability of the dosage form.[35-36]

TECHNIQUES FOR MATRIX SUSTAINED RELEASE TABLET DEVELOPMENT

Direct Compression

Direct compression stands as a prevalent method for crafting matrix sustained release tablets, especially when the active pharmaceutical ingredient (API) and other excipients exhibit compatible properties and good flowability. The process initiates with the precise blending of the API, matrix formers, release modifiers, and other necessary excipients to ensure a uniform distribution. Subsequently, this blend undergoes compression directly into tablets using a tablet press equipped with suitable tooling. This streamlined approach simplifies the manufacturing process, reducing both processing time and cost. Moreover, it aids in preserving API stability, particularly for heat-sensitive compounds. Direct compression offers notable advantages in terms of its simplicity and efficiency, making it a favored choice for the development of matrix sustained release tablets.[37-38]

Wet Granulation

Wet granulation emerges as a widely employed technique for matrix sustained release tablet development, particularly when dealing with APIs that are poorly compressible or possess unfavorable flow properties. The process commences with the granulation stage, where the API, matrix formers, and other excipients are blended and moistened with a granulating fluid, typically water or a solvent, to form wet granules. These wet granules are then subjected to drying to eliminate moisture content and enhance flow properties. Subsequently, the dried granules undergo milling to attain the desired particle size distribution. Finally, the milled granules are compressed into tablets using a tablet press. Wet granulation offers advantages such as improved flowability and compressibility of granules, enhanced content uniformity, and reduced risk of segregation during compression.[39-40]

Dry Granulation

Dry granulation, also known as slugging or roller compaction, serves as a preferred method for matrix sustained release tablet development, especially in scenarios where the API is sensitive to moisture or heat, or when the usage of solvent-based granulating fluids is impractical. The process commences with pre-compression, where the API and excipients are pre-compressed into large granules or slugs using a tablet press. These pre-compressed granules are subsequently milled to reduce particle size and improve flowability. Finally, the milled granules are compressed into tablets using a tablet press. Dry granulation offers advantages such as the preservation of API stability, avoidance of moisture or heat exposure, and improved flowability and compressibility of granules.[41-42]

Integration of Gastric Floating Drug Delivery Systems with Matrix Sustained Release Tablet Formulation Strategies

Selection of Polymers: The selection of polymers plays a crucial role in formulating GFDDS with matrix sustained release tablets. For floating properties, polymers with low density and high swelling capabilities, such as hydroxypropyl methylcellulose (HPMC), polyethylene oxide (PEO), and sodium alginate, are preferred. These polymers enable buoyancy and gastric retention of the dosage form. For sustained release properties, polymers with controlled release characteristics, such as HPMC, ethylcellulose, and polyvinyl acetate, are chosen. It's essential to ensure compatibility between the floating and sustained release polymers to achieve uniform distribution and consistent drug release kinetics throughout the dosage form.[43-44]

Coating Techniques: Coating techniques are employed to further enhance the performance of GFDDS with matrix sustained release tablets. Enteric coating is applied to the matrix tablet to prevent drug release in the acidic gastric environment and facilitate drug release in the alkaline environment of the small intestine, thereby maintaining the floating ability of the dosage form while ensuring site-specific drug release. Functional coatings may also be applied to modulate drug release kinetics, enhance drug stability, or provide additional protection against environmental factors. Layering techniques involving multiple polymer coatings can be utilized to achieve specific drug release profiles tailored to the therapeutic requirements.[45-46]

Manufacturing Methods: Manufacturing methods for GFDDS with matrix sustained release tablets include direct compression, wet granulation, and dry granulation. Direct compression offers simplicity and cost-effectiveness by directly compressing the blend of polymers, excipients, and drug particles into tablets. Wet granulation is employed for improved flow properties and compressibility of the formulation, with optimization of granulation parameters such as binder concentration and granulation time. Dry granulation may be considered

for APIs sensitive to moisture or heat, involving pre-compression of granules using roller compaction or slugging techniques before final compression into tablets. Each manufacturing method offers distinct advantages and considerations, depending on the specific requirements of the formulation and drug properties.[47-48]

In vitro and in vivo Evaluation

Floating Behavior

Floating behavior is assessed using various methods, including the USP dissolution apparatus with an adapted floating chamber or a density measurement method. The dosage form is placed in a dissolution medium, and the time duration and extent of floating are recorded. Floating behavior is crucial for ensuring gastric retention and prolonged drug release.[49]

Drug Release Kinetics

Drug release kinetics are evaluated using dissolution apparatus such as USP dissolution apparatus (e.g., paddle or basket method) or specialized dissolution setups for floating dosage forms. Samples are withdrawn at predetermined time intervals, and the amount of drug released is quantified using suitable analytical techniques. Different models like zero-order, first-order, Higuchi, and Korsmeyer-Peppas models may be used to analyze the release kinetics.[50]

Dissolution Profiles

Dissolution profiles are generated to assess the release characteristics of the integrated dosage form. Various dissolution parameters such as dissolution efficiency, dissolution rate, and similarity factors (e.g., f2) are calculated to compare the dissolution profiles of different formulations. This helps in understanding the release behavior and optimizing the formulation.[51-52]

In vivo Evaluation

Pharmacokinetic Profile

In vivo studies involve administering the integrated dosage form to animal models or human subjects, followed by blood sampling at predetermined time points. The concentration of the drug in plasma is determined using analytical techniques such as high-performance liquid chromatography (HPLC) or mass spectrometry (MS). Pharmacokinetic parameters such as Cmax, Tmax, AUC, and t1/2 are calculated to assess drug absorption, distribution, metabolism, and elimination.[53-54]

Gastrointestinal Transit

Gastrointestinal transit studies involve using imaging techniques such as gamma scintigraphy or magnetic resonance imaging (MRI) to monitor the movement of the integrated dosage form through the gastrointestinal tract. The retention time in the stomach and small intestine is determined to assess the gastric floating behavior and site-specific drug release.[55-56]

Bioavailability

Bioavailability studies involve comparing the plasma drug concentration-time profiles following oral administration of the integrated dosage form with those of reference formulations. Bioavailability parameters such as relative bioavailability and absolute bioavailability are calculated to assess the extent of drug absorption and systemic exposure.[57-58]

Table 1: Case Studies and Examples and Key Properties.

Case Study / Example	Description	Key Properties
Calcium silicate-based microspheres of repaglinide	Study focused on the development of floating sustained-release microspheres of repaglinide using calcium silicate as the floating matrix and HPMC as the sustained-release polymer.	- Floating behavior - Drug release kinetics - Size and morphology of microspheres - In vitro drug release profile - Compatibility of polymers
Floating-bioadhesive extended-release gliclazide tablet	Development and optimization of a floating-bioadhesive extended-release tablet of gliclazide using a combination of floating and sustained-release polymers, evaluated through in vitro and in vivo studies.	- Floating and bioadhesive properties - Drug release kinetics - In vitro dissolution profile - In vivo pharmacokinetic profile - Bioavailability - Gastric residence time
Enteric-coated floating matrix tablets for amoxicillin	Formulation and evaluation of enteric-coated floating matrix tablets for amoxicillin, combining floating polymers with enteric coating to achieve gastric retention and site-specific release in the intestine.	- Floating behavior - Enteric coating efficiency - Drug release profiles in gastric and intestinal fluids - Disintegration time - In vivo site-specific drug release - Pharmacokinetics - Bioavailability
Gastroretentive floating tablets of metformin hydrochloride	Development of gastroretentive floating tablets of metformin hydrochloride using a combination of floating and sustained-release polymers, evaluated for in vitro release and in vivo pharmacokinetics.	- Floating behavior - Drug release kinetics - In vitro dissolution profile - In vivo pharmacokinetic profile - Gastric residence time - Bioavailability - Gastrointestinal transit
Sustained-release floating tablets of	Formulation of sustained-release floating tablets of ranitidine hydrochloride employing a matrix	- Floating behavior - Drug release kinetics - Matrix erosion rate - In vitro

ranitidine hydrochloride	system with floating and sustained-release properties, evaluated through dissolution studies and pharmacokinetic analysis.	dissolution profile - In vivo pharmacokinetics - Gastric residence time - Bioavailability - Gastric emptying rate

Applications and Future Perspectives

The integration of gastric floating drug delivery systems (GFDDS) with matrix sustained release tablets holds promise across various therapeutic areas. Gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers can benefit from prolonged drug release and gastric retention, ensuring sustained therapeutic effect and improved patient compliance. Chronic diseases like diabetes, hypertension, and cardiovascular disorders often require long-term medication management, making sustained drug release formulations advantageous in maintaining optimal therapeutic levels over extended periods. Additionally, infectious diseases targeting the gastrointestinal tract can benefit from site-specific delivery and prolonged drug release, enhancing treatment efficacy. Furthermore, neurological disorders such as Parkinson's disease and epilepsy may benefit from controlled and sustained drug delivery to manage symptoms effectively.

The future of GFDDS-matrix tablet integration is ripe with potential innovations and developments. Targeted drug delivery systems could be developed, enabling precise delivery of drugs to specific regions of the gastrointestinal tract for enhanced therapeutic outcomes. Combination therapy, integrating multiple drugs with different release profiles into a single dosage form, could revolutionize treatment regimens by improving efficacy and patient adherence. Smart drug delivery systems, incorporating stimuli-responsive polymers or pH-sensitive coatings, offer the potential for on-demand drug release or tailored release profiles based on physiological conditions, enhancing therapeutic precision. Additionally, advancements in nanotechnology hold promise for improving drug loading capacity, bioavailability, and control over drug release kinetics, opening new avenues for drug delivery innovation.

Navigating regulatory considerations is paramount for the successful commercialization of integrated GFDDS-matrix tablet formulations. Compliance with pharmacopeial standards for dissolution, content uniformity, and other relevant parameters is essential to ensure product quality and performance. Bioequivalence studies may be required for generic products to demonstrate equivalence in drug release and pharmacokinetics compared to reference products. Long-term stability studies are necessary to assess the physical, chemical, and microbiological stability of the integrated dosage forms under various storage conditions, ensuring product integrity throughout its shelf life.

CONCLUSION

The integration of gastric floating drug delivery systems (GFDDS) with matrix sustained release tablets offers a synergistic approach to controlled drug delivery, with significant implications for various therapeutic areas. Key findings include the potential benefits across gastrointestinal disorders, chronic diseases, infectious diseases, and neurological disorders. Innovations such as targeted drug delivery, combination therapy, smart drug delivery systems, and nanotechnology hold promise for enhancing therapeutic outcomes. Regulatory considerations, including compliance with pharmacopeial standards, bioequivalence studies, and stability assessments, are crucial for successful commercialization. The commercial viability of integrated GFDDS-matrix tablet formulations is influenced by market trends, patient preferences, and regulatory requirements, underscoring the importance of strategic development and regulatory compliance.

Future directions and research opportunities in integrated GFDDS-matrix tablet formulations are vast and multifaceted. Continued research into targeted drug delivery systems, combination therapy approaches, and smart drug delivery technologies can further enhance therapeutic efficacy and patient adherence. Exploration of nanotechnology-based platforms for improved drug loading, bioavailability, and controlled release kinetics presents exciting avenues for innovation. Moreover, research focusing on personalized medicine, patient-centric drug delivery systems, and digital health technologies can drive advancements in precision medicine and improve patient outcomes. Collaboration between academia, industry, and regulatory agencies is essential for advancing knowledge, translating research findings into clinical practice, and addressing evolving healthcare challenges.

ACKNOWLEDGEMENT

We express our sincere gratitude to all authors contributed to the completion of this paper.

Conflict of Interest

No authors declared Conflict of Interest.

REFERENCES

1. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 2000; 63(3): 235-259. doi: 10.1016/s0168-3659(99)00204-7
2. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. doi: 10.3109/10837450903186216
3. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via

gastric retention. J Control Release, 2000; 63(3): 235-259. [DOI: 10.1016/s0168-3659(99)00204-7]
4. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
5. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res, 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825]
6. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Development and evaluation of effervescent floating matrix tablets of ciprofloxacin. AAPS PharmSciTech, 2007; 8(1): E1-E8. [DOI: 10.1208/pt0801001]
7. Khale DM, Foroughi R, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H. Formulation and optimization of floating-bioadhesive extended-release gliclazide tablet using response surface methodology: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 2017; 43(4): 590-602. [DOI: 10.1080/03639045.2016.1277384]
8. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm, 2003; 53(3): 199-212. [DOI: 10.1002/jps.20360]
9. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 2000; 63(3): 235-259. [DOI: 10.1016/s0168-3659(99)00204-7
10. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
11. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res, 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825
12. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
13. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216
14. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Development and evaluation of effervescent floating matrix tablets of ciprofloxacin. AAPS PharmSciTech, 2007; 8(1): E1-E8. [DOI: 10.1208/pt0801001]
15. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 2000; 63(3): 235-259. [DOI: 10.1016/s0168-3659(99)00204-7
16. Khale DM, Foroughi R, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H. Formulation and optimization of floating-bioadhesive extended-release gliclazide tablet using response surface methodology: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 2017; 43(4): 590-602. [DOI: 10.1080/03639045.2016.1277384]
17. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216
18. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm, 2003; 53(3): 199-212. [DOI: 10.1002/jps.20360]
19. Rathbone MJ, Hadgraft J, Roberts MS, Lane ME. Modified-Release Drug Delivery Technology. CRC Press; 2003.
20. Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications. CRC Press, 2012.
21. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
22. Langer R. Oral delivery of macromolecules: challenges, strategies, and future prospects. Ther Deliv, 2015; 6(8): 931-934. [DOI: 10.4155/tde.15.48]
23. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 2000; 63(3): 235-259. [DOI: 10.1016/s0168-3659(99)00204-7]
24. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Development and evaluation of effervescent floating matrix tablets of ciprofloxacin. AAPS PharmSciTech, 2007; 8(1): E1-E8. [DOI: 10.1208/pt0801001]
25. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release, 2000; 63(3): 235-259. [DOI: 10.1016/s0168-3659(99)00204-7]
26. Khale DM, Foroughi R, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H. Formulation and optimization of floating-bioadhesive extended-release gliclazide tablet using response surface methodology: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 2017; 43(4): 590-602. [DOI: 10.1080/03639045.2016.1277384]
27. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm

Res, 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825]
28. Khale DM, Foroughi R, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H. Formulation and optimization of floating-bioadhesive extended-release gliclazide tablet using response surface methodology: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 2017; 43(4): 590-602. [DOI: 10.1080/03639045.2016.1277384]
29. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
30. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm, 2003; 53(3): 199-212. [DOI: 10.1002/jps.20360]
31. Rathbone MJ, Hadgraft J, Roberts MS, Lane ME. Modified-Release Drug Delivery Technology. CRC Press; 2003.
32. Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications. CRC Press, 2012.
33. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
34. Langer R. Oral delivery of macromolecules: challenges, strategies, and future prospects. Ther Deliv, 2015; 6(8): 931-934. [DOI: 10.4155/tde.15.48]
35. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res, 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825]
36. Khale DM, Foroughi R, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H. Formulation and optimization of floating-bioadhesive extended-release gliclazide tablet using response surface methodology: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 2017; 43(4): 590-602. [DOI: 10.1080/03639045.2016.1277384]
37. Aulton ME, Taylor K. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier Health Sciences, 2017.
38. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. Lea & Febiger, 1986.
39. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Lea & Febiger; 1986.
40. Leon L, Rohera B, Serra J. Tablet Compression: Machine Theory and Practice. CRC Press, 2007.
41. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. Lea & Febiger, 1986.
42. Leon L, Rohera B, Serra J. Tablet Compression: Machine Theory and Practice. CRC Press; 2007.
43. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
44. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. Lea & Febiger, 1986.
45. Watanabe T, Matsumoto M. Gastroretentive drug delivery systems. In: Kim I, editor. Fundamentals and Applications of Controlled Release Drug Delivery. In Tech Open, 2012.
46. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
47. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Lea & Febiger; 1986.
48. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
49. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
50. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res. 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825]
51. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 2001; 13(2): 123-133. [DOI: 10.1016/s0928-0987(01)00095-1]
52. Khale DM, Foroughi R, Barzegar-Jalali M, Javadzadeh Y, Hamishehkar H. Formulation and optimization of floating-bioadhesive extended-release gliclazide tablet using response surface methodology: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 2017; 43(4): 590-602. [DOI: 10.1080/03639045.2016.1277384]
53. Aulton ME, Taylor K. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier Health Sciences, 2017.
54. Langer R. Oral delivery of macromolecules: challenges, strategies, and future prospects. Ther Deliv, 2015; 6(8): 931-934. [DOI: 10.4155/tde.15.48]

55. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Pharm Dev Technol, 2010; 15(4): 377-383. [DOI: 10.3109/10837450903186216]
56. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res, 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825]
57. Aulton ME, Taylor K. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier Health Sciences, 2017.
58. Desai S, Bolton S. A floating controlled-release drug delivery system: in vitro-in vivo evaluation. Pharm Res, 1993; 10(9): 1321-1325. [DOI: 10.1023/a: 1018985621825]